POSC163 Cost-Utility Analysis of Empagliflozin in Chronic Heart Failure with Reduced Ejection Fraction: A UK Healthcare System Perspective
Jan 1, 2022, 00:00 AM
10.1016/j.jval.2021.11.565
https://www.valueinhealthjournal.com/article/S1098-3015(21)02360-3/fulltext
Section Title :
Section Order :
10101
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02360-3&doi=10.1016/j.jval.2021.11.565